PT  - JOURNAL ARTICLE
AU  - Rezaie, Ali
AU  - Melmed, Gil Y.
AU  - Leite, Gabriela
AU  - Mathur, Ruchi
AU  - Takakura, Will
AU  - Pedraza, Isabel
AU  - Lewis, Michael
AU  - Murthy, Rekha
AU  - Chaux, George
AU  - Pimentel, Mark
TI  - Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study
AID  - 10.1101/2021.03.05.21252997
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.05.21252997
4099  - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252997.short
4100  - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252997.full
AB  - Background Promising preclinical experiments show that, under specific and monitored conditions, ultraviolet-A (UVA) exposure reduces certain bacteria, fungi, and viruses including coronavirus-229E without harming mammalian columnar epithelial cells. We aimed to evaluate the safety and effects of UVA therapy administered by a novel device via endotracheal tube in critically ill subjects with SARS-CoV-2 infection.Methods Five newly intubated mechanically ventilated adults with SARS-CoV-2 infection, with an endotracheal tube size 7.5mm or greater, were treated with UVA for 20 minutes daily for 5 days, and followed for 30 days.Results Five subjects were enrolled (mean age 56.6yrs, 3 male). At baseline, all subjects scored 9/10 on the WHO clinical severity scale (10=death) with predicted mortality ranging from 21 to 95%. Average log changes in endotracheal viral load from baseline to day 5 and day 6 were -2.41 (range -1.16 to -4.54; Friedman P=0.002) and -3.20 (range -1.20 to -6.77; Friedman P<0.001), respectively. There were no treatment-emergent adverse events. One subject died 17 days after enrollment due to intracranial hemorrhagic complications of anticoagulation while receiving extracorporeal membrane oxygenation. The remaining subjects clinically improved and scored 2, 4, 5, and 7 on the WHO scale at day 30. In these subjects, the slope of viral load reduction during UVA treatment correlated with the slope of improvement in clinical WHO severity score over time (Spearman rho=1, P<0.001).Conclusion In this first-in-human study, endotracheal UVA therapy under specific and monitored settings, was safe with a significant reduction in respiratory SARS-CoV-2 viral burden over the treatment period.Trial Registration ClinicalTrials.gov #NCT04572399.Key MessagesWhat is the key question?Can endotracheal narrow-band UVA therapy be a safe and effective treatment for severe SARS-CoV-2 infection?What is the bottom line?Under specific and monitored settings, endotracheal UVA light therapy may be an effective treatment for SARS-CoV-2 infection. Endotracheal UVA light therapy appears to be well tolerated in critically ill patients with SARS-CoV-2 infection.Why read on?This is the fist-in-human trial of internal UVA therapy using a alternative novel approach to combat COVID-19.Competing Interest StatementThis investigator-initiated study was sponsored by Aytu Biosciences. Cedars-Sinai Medical Center has a licensing agreement with Aytu BioSciences. Cedars-Sinai has a patent on internal UV therapy, inventors: AR, MP, GYM, RM and GL. All other authors do not have any relevant conflict of interest. None of the authors receive salary or consulting fees or have any equity, shares, or options at Aytu Biosciences.Clinical TrialNCT04572399Funding StatementThis investigator-initiated study was sponsored by Aytu Biosciences. The study sponsor had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review, and approval of the manuscript, or the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the institutional review board of Cedars-Sinai, Los Angeles, CA, USAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are in the manuscript and supporting files